Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07506876 · ClinicalTrials.gov registry record · Phase 2
Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer
A Phase 2 study, sponsored by Legacy Health System.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07506876 is a Phase 2 study that is actively recruiting participants, run by Legacy Health System. The registered enrollment target is 30 participants.
The verdict
NCT07506876, a Phase 2 study, is actively recruiting participants, sponsored by Legacy Health System.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The usual approach to care for hormone receptor positive, HER2 positive breast cancer is chemotherapy and HER2 targeted therapy followed by endocrine therapy and surgery. The purpose of this Research Study is to see if taking endocrine therapy with the chemotherapy and HER2 directed therapy increases patients response to therapy at the time of surgery
Interventions
- DRUG Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-04-27 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07506876
The ClinicalTrials.gov registry entry for NCT07506876 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Legacy Health System, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy is the first listed.
NCT07506876 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07506876 about?
NCT07506876 is a clinical study titled "Concurrent Neoadjuvant Chemo/Endocrine Therapy in HER2+ Breast Cancer". The usual approach to care for hormone receptor positive, HER2 positive breast cancer is chemotherapy and HER2 targeted therapy followed by endocrine therapy and surgery. The purpose of this Research Study is to see if taking endocrine therapy with the chemotherapy and HER2 directed therapy increas...
What is the current status of trial NCT07506876?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-04-27. Estimated completion is 2027-12.
What interventions are being tested in trial NCT07506876?
The interventions under investigation include: Concurrent endocrine therapy with the chemotherapy and HER2 directed therapy (DRUG).
Who is sponsoring clinical trial NCT07506876?
This trial is sponsored by Legacy Health System, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.